We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 15, 2021

Predictive Genomic Biomarkers of Hormonal Therapy vs Chemotherapy Benefit in Metastatic Castration-Resistant Prostate Cancer

European Urology


Additional Info

Disclosure statements are available on the authors' profiles:

European Urology
Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer
Eur Urol 2021 Oct 26;[EPub Ahead of Print], RP Graf, V Fisher, J Mateo, OV Gjoerup, RW Madison, K Raskina, H Tukachinsky, J Creeden, R Cunningham, RSP Huang, DA Mata, JS Ross, GR Oxnard, JM Venstrom, AJ Zurita

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading